Research Group Andreas Wicki


Oncology, Precision Medicine, Therapy Prediction, Functional and Multi-Omics Testing

Summary & Mission statement

The Experimental Oncology Research Group has a focus on improving therapy outcomes in oncology by combining deep analysis of tumor tissue (functional & single-cell omics) with state-of-the-art data science.


State-of-the-art high throughput platforms are used to assess tens of thousands of biomarkers from solid or liquid samples within the time-frame of two weeks. Data is used for support of therapy decisions at the molecular board (fast diagnostic loop) and mined through machine-based learning and artificial intelligence for diagnostic, prognostic and predictive information (exploratory loop). The platforms support both the MOH Personalized Oncology Program, and the Swiss-wide Precision Oncology Program (SPO) of the Swiss Personalized Health Network. From 2018 to 2021, patients with melanoma,ovarian cancer and acute myeloid leukemia (AML) were included and analysed by TPC. From 2023 to 2026, additional cohorts of patients with breast cancer, lung cancer and colorectal cancer will be activated and recruit patients.


See Publications


The Tumor Profiler Trial: the study workflow entails patient enrollment, sample collection, analysis by different technology platforms and data integration, creation and discussion of molecular research and summary reports, discussion of treatment options in pre-tumor boards, the final treatment decision and assessment of outcome. Irmisch et al. Cancer Cell. 2021